Concurrent SARS-CoV-2 and Influenza Infections Among People Tested at US Pharmacies
-
By
-
Pragna Patel
-
Jessica K. Sprinkles
-
Andrew Godoshian
-
Marcus Siddall
-
Timothy M. Uyeki
-
Henry Walke
-
Joseph Miller
-
November 18, 2026
Clinical Scorecard: Concurrent SARS-CoV-2 and Influenza Infections Among People Tested at US Pharmacies
At a Glance
Category | Detail |
|---|---|
Condition | Concurrent SARS-CoV-2 and influenza infection (coinfection) |
Key Mechanisms | Coinfection is identified by positive tests for both SARS-CoV-2 and influenza; the article notes prior evidence linking coinfection with higher risk of severe outcomes. |
Target Population | People tested for SARS-CoV-2 and influenza A and B at participating US pharmacies from September 1, 2023, through May 31, 2025. |
Care Setting | Community pharmacies participating in the Increasing Community Access to Testing, Treatment, and Response program. |
Key Highlights
Among 817,834 people tested, 665 (0.1%) tested positive for both viruses; estimated coinfection prevalence was 0.081% (95% CI, 0.075%-0.087%).
Coinfection prevalence was highest among children younger than 18 years (0.145%); adjusted odds were higher than among adults aged 18 to 64 years (OR, 1.93; 95% CI, 1.42-2.57).
Among 665 people with coinfection, 26 (3.9%) received COVID-19 treatment and 29 (4.4%) received influenza treatment; none received treatment for both infections.
Among 144 symptomatic people with coinfection who reported health histories, 63.9% reported no comorbidities; cough, headache, and congestion were the most common symptoms.
The authors note that pharmacy clinicians might consider prompt COVID-19 and/or influenza therapy for symptomatic people vulnerable to severe outcomes.
Guideline-Based Recommendations
Diagnosis
The study defined coinfection as positive tests for both SARS-CoV-2 and influenza virus.
Testing used a multiplex SARS-CoV-2/influenza A and B assay or a laboratory-based nucleic acid amplification test.
Management
For symptomatic people vulnerable to severe outcomes, pharmacy clinicians might consider prompt COVID-19 and/or influenza therapy during respiratory season, according to the article.
The article reports that antiviral medications may lower the risk of severe COVID-19 and certain influenza complications.
Monitoring & Follow-up
The study assessed antiviral dispensing, but available data on symptoms, comorbidities, severity, treatment, and outcomes were limited by nonresponse and prescriptions received elsewhere.
Risks
Prior investigations cited by the article linked SARS-CoV-2 and influenza coinfection with higher risk of severe outcomes.
Coinfection odds were lower among people aged 65 years or older than among those aged 18 to 64 years (OR, 0.69; 95% CI, 0.53-0.89).
Patient & Prescribing Data
The cohort included 817,834 pharmacy-tested people across 50 states, the District of Columbia, and Puerto Rico; median age was 40 years, and 61.2% were female.
Of 665 people with coinfection, 26 received COVID-19 treatment and 29 received influenza treatment; no one received treatment for both. Among coinfected adults aged 18 to 64 years with at least one comorbidity, 19 of 42 (45.2%) received each type of treatment.
Clinical Best Practices
Use multiplex testing to identify concurrent SARS-CoV-2 and influenza infection in community pharmacy settings.
Consider prompt COVID-19 and/or influenza therapy for symptomatic people vulnerable to severe outcomes, as stated by the article.
Interpret treatment and symptom findings in light of incomplete survey responses and prescriptions that may have been obtained elsewhere.
Related Resources & Content
JAMA Network Open, 2026 -- SARS-CoV-2 and Influenza Coinfection Among Persons Tested in US Pharmacies
Centers for Disease Control and Prevention, 2026 -- Clinical Guidance for Hospitalized and Non-Hospitalized Patients When SARS-CoV-2, RSV, and Influenza Viruses are Co-Circulating
Centers for Disease Control and Prevention, 2026 -- Influenza Antiviral Medications: Summary for Clinicians
Centers for Disease Control and Prevention, 2026 -- Multiplex Tests to Detect Influenza, SARS-CoV-2, and RSV
Infectious Diseases Society of America, 2026 -- IDSA Guidelines on the Treatment and Management of Patients with COVID-19
the pathologist — Shifts in Influenza Activity 2018 to 2023
MDSpire News — COVID-19 & Flu Vaccines Study: Comparable Safety
the pathologist — Flu Season in the Time of COVID-19
mdspire news — Same-Day COVID, Flu Vaccination Appears Safe
Clinical Guidance for Hospitalized and Non-Hospitalized Patients When SARS-CoV-2, RSV, and Influenza Viruses are Co-Circulating
Influenza Antiviral Medications: Summary for Clinicians
Multiplex Tests to Detect Influenza, SARS-CoV-2, and RSV
IDSA Guidelines on the Treatment and Management of Patients with COVID-19
SARS-CoV-2 and Influenza Coinfection Among Persons Tested in US Pharmacies | Infectious Diseases | JAMA Network Open | JAMA Network
Clinical impact of coinfection with SARS-CoV-2, influenza virus, and respiratory syncytial virus among adults: a multicenter retrospective cohort study [2021–2025]
Severe outcomes of individual or multiple respiratory viral infections in a large national healthcare system, 2022–2023
Based on findings from:
SARS-CoV-2 and Influenza Coinfection Among Persons Tested in US Pharmacies
Pragna Patel, Jessica K. Sprinkles, Andrew Godoshian, Marcus Siddall, Timothy M. Uyeki, Henry Walke, Joseph Miller. Jama Network Open, 2026.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2856777
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.